Hospira, Inc. (NYSE: HSP:), a leading global specialty pharmaceutical and medication delivery company, recently announced that the company will present at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, Dec. 2, 2009 in New York City.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The presentation is scheduled to begin at 9:30 a.m. Eastern time on Wednesday, Dec. 2, 2009. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the audiocast. The slides accompanying the presentation will be available on the Hospira Web site. A replay of the webcast will be available on the Hospira Web site approximately 24 hours after the live presentation for 30 days after the event. Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees.
Sign up for the free Best Damn Penny Socks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
